To close this gap, our objective was to compare the costs and QALYs of different risk-reducing strategies available for healthy women with no personal history of BC or OC who have been tested positive for BRCA1 or BRCA2 in Switzerland and to estimate associated costs and health implications, using health-economic modelling. This evidence concerns the gene BRCA2 and breast cancer.